Clinical Trials Browser

Pathologic Complete Response

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Gynecologic

Pathologic Complete Response, Ovarian Neoplasms

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

127 enrolled

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 2 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

264 enrolled

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Lymphoid

Pathologic Complete Response, Lymphoma, Follicular

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01648894 2022-07-25

GRECCAR6

Phase 3 Completed

265 enrolled

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT02613026 2015-11-24

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Phase 3 Completed

104 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 3 Unknown

480 enrolled

Plasma cell

Pathologic Complete Response, Multiple Myeloma

NCT00378222 2006-09-19

Autologous Transplantation for Multiple Myeloma

Phase 3 Completed

324 enrolled

Plasma cell

Pathologic Complete Response, Multiple Myeloma

Clinical Trials

MEND-IT II

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

SOLO-1

REGAL

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

QUAZAR AML-001

ATHENA

PTCy-PMAT

2002

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

GRECCAR6

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Autologous Transplantation for Multiple Myeloma